MegaRobo Technologies, a Chinese start-up that uses artificial intelligence and robotics in life sciences research, has raised $300 million in a funding round led by Goldman Sachs Asset Management, Asia Investment Capital and GGV Capital.
The six-year-old company is the latest start-up from the pharmaceutical industry to capitalize on a jump in investor interest in the sector after the COVID-19 pandemic.
Get the week’s top news delivered directly to your inbox – Sign up for our newsletter
Market research platform AlphaSense also raised $225 million on Wednesday in a funding round that valued it at $1.7 billion, while biotechnology firm Synthego earlier this year raised $200 million in a fundraise led by hedge fund Perceptive Advisors, with participation from SoftBank Vision Fund 2.
Source: Reuters
Can’t stop reading? Read more
Copenhagen Infrastructure Partners secures €1.3bn first close for flagship green credit fund
Copenhagen Infrastructure Partners secures €1.3bn first close for flagship green credit fund...
Ontario Teachers’ reports 6.7% return as assets reach $279.4bn
Ontario Teachers’ reports 6.7% return as assets reach $279.4bn Ontario Teachers’ Pension Plan...
BNP Paribas gathers €540m for GP stakes strategy targeting private capital managers
BNP Paribas gathers €540m for GP stakes strategy targeting private capital managers BNP Paribas...